Nuvilex (PMCB) News Today $1.08 -0.02 (-1.51%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$1.10 +0.02 (+2.22%) As of 07/11/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMCB Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period MyMD Pharmaceuticals Secures Strategic InvestmentsMay 21, 2024 | businesswire.comPharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseMay 21, 2024 | businesswire.comPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024December 18, 2023 | msn.comCompanies Like PharmaCyte Biotech (NASDAQ:PMCB) Are In A Position To Invest In GrowthDecember 15, 2023 | finance.yahoo.comPharmaCyte Biotech Inc PMCBDecember 5, 2023 | morningstar.comMPharmaCyte Biotech Invests In Femasys - Quick FactsNovember 15, 2023 | markets.businessinsider.comFemasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte BiotechNovember 15, 2023 | finance.yahoo.comPharmaCyte completes tender offer to purchase sharesJune 15, 2023 | msn.comPharmaCyte Biotech Announces Final Results of Tender OfferJune 15, 2023 | finance.yahoo.comLos Angeles Biotech NewsJune 14, 2023 | bizjournals.comPharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per ShareMay 11, 2023 | finance.yahoo.comBiotech ETFs’ Performance Deserves A LookApril 21, 2023 | nasdaq.com300 biotech and pharma CEOs including the head of Pfizer call for a reversal of the abortion pill banApril 12, 2023 | fortune.comA 45-year-old biotech CEO may have reduced his biological age by at least 5 years through a rigorous medical program that can cost up to $2 million a year, Bloomberg reportedFebruary 2, 2023 | msn.comPharmaCyte Biotech to Implement Second $10-Million Share Repurchase PlanFebruary 2, 2023 | finance.yahoo.comPharmaCyte to evaluate opportunities; CEO steps downOctober 7, 2022 | seekingalpha.comPharmaCyte Names Joshua Silverman Interim CEO As CEO Kenneth Waggoner Steps DownOctober 7, 2022 | markets.businessinsider.comPharmaCyte Biotech Reaches Cooperation Agreement with Iroquois CapitalAugust 15, 2022 | finance.yahoo.comIroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.July 28, 2022 | finance.yahoo.comPharmaCyte Biotech Commences First Phase of Two-Phase Pig StudyJuly 21, 2022 | finance.yahoo.comIROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORSJuly 11, 2022 | finance.yahoo.comPharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022July 11, 2022 | finance.yahoo.comPharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap CellsJuly 5, 2022 | finance.yahoo.comIROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETINGJune 23, 2022 | finance.yahoo.comPharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder ValueJune 17, 2022 | stockhouse.comPharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder ValueJune 15, 2022 | finance.yahoo.comPharmaCyte Biotech to Attend 2022 BIO International Convention in San DiegoJune 13, 2022 | finance.yahoo.comPharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder ValueJune 8, 2022 | finance.yahoo.comPharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for DiabetesApril 27, 2022 | finance.yahoo.comPharmaCyte Biotech Shares Reverse Course, Drop 8%April 19, 2022 | marketwatch.comPharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA RequirementsApril 19, 2022 | finance.yahoo.comPharmaCyte gets on with preparations for pancreatic cancer trial amid FDA clinical holdApril 13, 2022 | seekingalpha.comPharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical TrialApril 13, 2022 | finance.yahoo.comPharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of DirectorsApril 5, 2022 | finance.yahoo.comPharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product CandidateMarch 22, 2022 | finance.yahoo.comPharmaCyte Biotech (OTCMKTS:PMCB) Raised to Buy at Zacks Investment ResearchMarch 19, 2022 | marketbeat.comPharmaCyte Biotech reports Q3 resultsMarch 18, 2022 | seekingalpha.comPharmaCyte Biotech Reports Third Quarter Financial Results and Operational HighlightsMarch 16, 2022 | finance.yahoo.comPharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of IntegrationFebruary 22, 2022 | finance.yahoo.comPharmaCyte Biotech (OTCMKTS:PMCB) Downgraded by Zacks Investment ResearchFebruary 16, 2022 | marketbeat.comPharmaCyte Biotech Updates Status of Investigational New Drug Application to FDAFebruary 14, 2022 | finance.yahoo.comPharmaCyte Biotech (OTCMKTS:PMCB) Upgraded to "Buy" by Zacks Investment ResearchJanuary 11, 2022 | marketbeat.comPharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated CellsJanuary 4, 2022 | finance.yahoo.comPharmaCyte Biotech Reports Q2 2021 Cash On Hand $87MDecember 16, 2021 | benzinga.comPharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational HighlightsDecember 15, 2021 | finance.yahoo.com5 Penny Stocks With Long-Term Growth CatalystsOctober 5, 2021 | insidermonkey.comPharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNASeptember 27, 2021 | finance.yahoo.comPharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility TestsSeptember 21, 2021 | finance.yahoo.comThinking about buying stock in Camber Energy, Farmmi, Offerpad Solutions, Pharmacyte Biotech, or Barrick Gold?September 16, 2021 | benzinga.comPharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDASeptember 16, 2021 | finance.yahoo.com Get Nuvilex News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Email Address PMCB Media Mentions By Week PMCB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PMCB News Sentiment▼1.871.01▲Average Medical News Sentiment PMCB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PMCB Articles This Week▼10▲PMCB Articles Average Week Get Nuvilex News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SNYR News Today MRNS News Today OVID News Today ALLK News Today DYAI News Today INKT News Today COEP News Today NRSN News Today SCYX News Today ENLV News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PMCB) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvilex Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PMCB Stock Alerts